Athira Pharma, Inc. Common Stock (ATHA)
Athira Pharma, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases, including Alzheimer's disease. Founded with the goal of addressing the underlying causes of neurodegeneration, the company leverages its proprietary small molecule platform to discover and develop novel treatments aimed at restoring neuronal health and function.
Company News
Athira Pharma reported Q2 2025 financial results, focusing on cost reduction and advancing its ALS drug candidate ATH-1105. The company narrowed its net loss, reduced R&D expenses, and completed a Phase 1 clinical trial, but faces challenges in securing partnerships and maintaining cash reserves.
Athira Pharma announced positive results from a Phase 1 clinical trial of its drug candidate ATH-1105 in healthy volunteers, supporting continued development for the potential treatment of amyotrophic lateral sclerosis (ALS). The company plans to initiate a clinical trial in ALS patients in late 2025.
Athira Pharma has dosed the last patient in the phase II/III LIFT-AD study evaluating its pipeline candidate, fosgonimeton, for the treatment of mild-to-moderate Alzheimer's disease. The study is designed to assess the treatment effects of fosgonimeton across multiple aspects of the disease.
The Dow Jones index closed lower by around 20 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider...